

ASX Announcement

Suspension and Half Year Financials Update

SYDNEY 22 March 2024– Allegra Medical Technologies (Allegra) (ASX: AMT) advises Shareholders that, further to the request for an extension to the voluntary suspension on 8th March 2024, the Company has been placed into an ASX imposed suspension in accordance with ASX Listing Rule 17.3.

The Company further confirms that Appendix 4D and Half Year Report, has been finalised and announced to the market on 22nd March 2024.

The ongoing support of the financiers continues to be discussed, negotiated, and assuming satisfactory terms can be agreed, documented. This is envisaged to take up to an additional 2 weeks. Should these discussions complete earlier, the Company will advise the market.

The funding arrangements provide the ability for the Company to proceed with the sale of the intellectual property relating to the Sr-HT-Gahnite Spinal Cage Device.

This announcement has been authorised for release by the CEO of Allegra.

Contact details:

Robyn Slaughter
Company Secretary
T: +61 2 8072 1435

ABOUT ALLEGRA MEDICAL TECHNOLOGIES:

Allegra Medical Technologies (AMT), a listed biotechnology company on the Australian Securities Exchange (ASX), is at the forefront of innovation in the medical device industry with its pioneering 3D-printed Sr-HT and Sr-HT-Gahnite orthopaedic devices. AMT holds exclusive ownership of this groundbreaking bio ceramic material, along with registered patents and patent applications from the University of Sydney. This versatile material has several applications, including its use as a cervical fusion cage in spinal surgeries, offering safe and effective treatment options for patients. The development of Sr-HT ceramic material began in 2010 at The University of Sydney, demonstrating the bioactivity required for bone regeneration. Subsequently, Sr-HT-Gahnite was developed, featuring bioactivity, biocompatibility, and mechanical properties suitable for load-bearing orthopaedic implants. AMT boasts a dedicated, highly qualified engineering team with a clear mandate to explore, collaborate, and transform early-stage innovations into commercially viable products. Their primary focus currently centres on commercializing the Sr-HT Gahnite Bone substitute.

Allegra Medical Technologies Limited

Level 8, 18 --- 20 Orion Rd, Lane Cove West NSW 2066 Australia; PO Box 72 St Leonards NSW 2065 Australia

T +612 9119 9200 **T** Toll Free 1800 644 370

F +612 9439 4441 **F** Toll Free 1800 624 223

E sales@allegraorthopaedics.com

www.allegraorthopaedics.com